share_log

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

每日生物技术脉搏:美国食品和药物管理局希望奥密克戎靶向新冠疫苗加强针,预防糖尿病药物生物清除障碍,牛津生物医疗,阿斯利康Strike疫苗协议
Benzinga Real-time News ·  2022/07/01 08:54
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是过去24小时生物技术领域的热门发展综述:
Stocks In Focus
关注的股票
FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants
美国食品和药物管理局专家小组青睐新冠疫苗加强针针对奥密克戎BA.4、BA.5亚型
The FDA's independent experts voted to include a SARS-CoV-2 omicron component in COVID-19 vaccines that would be used for boosters in the U.S. beginning in fall 2022.
FDA的独立专家投票决定,在奥密克戎疫苗中加入SARS-CoV-2新冠肺炎成分,从2022年秋季开始,新冠肺炎将在美国用于加强免疫。
The panel has advised manufacturers to develop modified vaccines that add an omicron BA.4/5 spike protein component to the vaccine composition to create a two-component (bivalent) booster vaccine.
该小组建议制造商开发改进后的疫苗,在疫苗成分中添加奥密克戎BA.4/5刺突蛋白成分,以创建双组分(双价)加强疫苗。
Genmab Plans To File US Application For Epcoritamab In Blood Cancer Setting
Genmab计划在美国申请Epcoritamab用于血癌治疗
Genmab...
G...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发